Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study.

ABSTRACT:

Background

The real-world incidence of chronic liver damage after transarterial chemoembolization (TACE) is unclear. LiverT, a retrospective, observational study, assessed liver function deterioration after a single TACE in real-world hepatocellular carcinoma (HCC) patients in US practice.

Methods

Eligible HCC patients identified from Optum's integrated database using standard codes as having had an index TACE between 2010 and 2016 with no additional oncologic therapy in the subsequent 3 months. At least one laboratory value (bilirubin, albumin, aspartate transaminase [AST], alanine transaminase [ALT], international normalized ratio [INR]) was required at baseline and the acute (≤29 days after TACE) and chronic (30-90 days after TACE) periods. Due to lack of universally acce

SUBMITTER: Miksad RA 

PROVIDER: S-EPMC6693268 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature